Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended			12 Months Ended
		Jan. 31, 2023	Mar. 31, 2023		Mar. 31, 2022	Dec. 31, 2022
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance			2,000,000
Shares available for issue			416,914
Number of common stock purchased			573,229		194,240
Proceeds from common stock			$ 182		$ 218
Treasury stock			188,846
Number of shares available for issue		250,000
Lucid Diagnostics Inc [Member] | Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance			1,000,000
Shares available for issue			683,983
Number of common stock purchased			231,987
Proceeds from common stock			$ 276
Number of shares available for issue		500,000
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance			21,052,807
Shares available for issue		4,700,000	751,778
Number of stock options outstanding			600,854
Weighted average fair value of stock options			$ 0.35		$ 1.22
Number of shares available for issue			500,854		500,854
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding			5,052,458	[1]		2,565,377
Number of stock options outstanding	[2]		2,697,500
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance			11,644,000
Shares available for issue		2,500,000	3,834,058
Number of stock options outstanding			423,300			423,300
Number of restricted stock awards granted outstanding			50,000
Weighted average fair value of stock options			$ 0.87		$ 2.95

[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2023 and December 31, 2022.

[2] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.